AU Patent

AU2021218120A1 — Fixed dose combinations and formulations comprising ETC1002 and Ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Assigned to Esperion Therapeutics Inc · Expires 2021-09-09 · 5y expired

What this patent protects

Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herien are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a su…

USPTO Abstract

Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herien are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject. 35

Drugs covered by this patent

Patent Metadata

Patent number
AU2021218120A1
Jurisdiction
AU
Classification
—
Expires
2021-09-09
Drug substance claim
No
Drug product claim
No
Assignee
Esperion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.